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Abstract:  It  has  been  known  for  some  time  that  the  HIV  Rev  protein  binds  and 
oligomerizes  on  a  well-defined  multiple  stem-loop  RNA  structure,  named  the  Rev 
Response Element (RRE), which is present in a subset of HIV mRNAs. This binding is the 
first step in a pathway that overcomes a host restriction, which would otherwise prevent the 
export of these RNAs to the cytoplasm. Four recent publications now provide new insight 
into the structure of Rev and the multimeric RNA-protein complex that forms on the RRE 
[1–4]. Two unexpected and remarkable findings revealed in these studies are the flexibility 
of RNA binding that is demonstrated by the Rev arginine-rich RNA binding motif, and the 
way that both Rev protein and RRE contribute to the formation of the complex in a highly 
cooperative fashion. These studies also define the Rev dimerization and oligomerization 
interfaces to a resolution of 2.5Å, providing a framework necessary for further structural 
and functional studies. Additionally, and perhaps most importantly, they also pave the way 
for rational drug design, which may ultimately lead to new therapies to inhibit this essential 
HIV function. 
Keywords: HIV-1; Rev; RRE; RNA export; nuclear-cytoplasmic export; protein structure; 
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It has been 25 years since the first publications established that the HIV rev gene is essential for 
HIV replication ([5,6]; for a review see [7]). The product of this gene, the Rev protein, binds to the 
Rev Response Element (RRE) [8–16], a multiple stem-loop RNA element, present in unspliced and 
incompletely spliced HIV mRNAs [17–19]. This binding is an essential step in a series of events that 
OPEN ACCESS Viruses 2011, 3                         
 
 
485 
leads to the nucleo-cytoplasmic export of these mRNAs. Without Rev, they would be restricted by the 
cell from exiting the nucleus, because they retain introns [20,21]. Over the years, the study of Rev has 
led to important discoveries in the nuclear export field, including the discovery of the “leucine rich” 
nuclear export signal (NES) [22–25] and its binding partner, the export receptor Crm-1, also called 
Exportin-1  [26–29].  However,  many  of  the  structural  details  about  Rev-RRE  interactions  have 
remained obscure, due primarily to a lack of structural information about Rev itself.  
This situation has now changed with the appearance of a trio of papers from Alan Frankel‟s lab  
[1–3], and one from a collaborative group of investigators at NIH and the Welcome Trust [4]. As a 
result of these publications, we now have a partial crystal structure for Rev, and an elegant structural 
model to describe how Rev binds to the RRE, oligomerizes, and forms the RNA-protein complex 
which serves as the export substrate for Crm-1. 
Rev and RRE are HIV‟s way of solving a host restriction that every retrovirus must overcome. This 
restriction arises because retroviral genetic organization makes the coding region for Gag and GagPol 
an intron that has to be removed to generate the spliced mRNA that expresses the envelope protein 
[30]. Thus, all retroviruses must export at least one mRNA from the nucleus that retains at least one 
intron. This RNA also serves as the genome to be packaged into new virus particles. In HIV, there is 
an additional second intron that roughly spans the envelope protein coding region, and alternative 
splicing generates multiple mRNAs for the accessory and regulatory proteins (including Rev) [31]. 
This complex RNA processing pattern brings about the necessity for HIV to export multiple mRNAs 
with retained introns.  
It has been well established that mammalian cells do not normally allow mRNA with retained 
introns to reach the cytoplasm [20,21]. In the instances when such export does occur, special processes 
appear to be used. In some cases, this involves cis-acting RNA sequence elements (called CTEs) which 
link the intron-containing RNA directly to the Nxf1 mRNA export pathway [32,33]. This pathway is 
believed to be the major RNA export pathway used in mammalian cells and at least one retrovirus, 
Mason-Pfizer Money Virus, seems to have directly “stolen” this process from the cellular gene [34,35]. 
Other retroviruses, such as HTLV-I [36,37], MMTV [38], EIAV [39,40], and Jaagsiekte Sheep virus 
[41–43] employ viral specific components that work like Rev and RRE, but which show very little 
sequence similarity. These viruses, like HIV, thus use a virally encoded protein and a viral RNA 
adapter sequence to link mRNA export to the Crm-1 pathway. Recently the human foamy virus group 
of retroviruses has been shown to use a different mechanism to link export to Crm-1, relying on the 
cellular protein HuR protein as an RNA-binding adapter [44]. Why some viruses like HIV and HTLV 
evolved to use their own virally encoded proteins to link RNA export to the cellular Crm-1 export 
pathway remains a mystery. 
For many years, a known feature of RNA binding by Rev has been the ability of the protein to form 
oligomers on a single RNA molecule [8,12,14,45–47] and several earlier studies have shown that Rev 
oligomerization is a necessary event for biological function. Some early reports suggested that Rev 
dimerizes first and then binds to the RRE [48,49], but there is now strong evidence that Rev recognizes 
its primary binding site as a monomer  [50]. The RRE displays a complicated secondary structure 
within the HIV RNA that contains several “stems” and “loops [46,51]. The Rev primary binding site is 
formed by unusual features in the stem loop IIB region, including an A:G base pair and a distortion of 
the RNA helix [52,53]. The structure of this region of the RRE in complex with a peptide that mimics Viruses 2011, 3                         
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the  RNA  binding  domain  of  Rev  was  determined  some  time  ago.  In  this  structure,  the  basic  
arginine-rich peptide inserts deeply into a wide RNA major groove, making specific contacts with the 
A:G base pair [54,55]. 
Two of the three papers by Daugherty et al. have now re-examined the nature and kinetics of  
Rev-RRE binding [1,2]. These studies show very clearly that assembly of the export complex is a  
well-orchestrated duet between RRE and Rev, involving the assembly of most likely six monomers of 
Rev on one RRE. This is a highly cooperative event, which relies upon the Rev protein‟s RNA binding 
and oligomerization domains, as well as the RRE itself. The complex formed by this cooperative 
binding has an affinity that is 500-times greater than that of the tightest single interaction. What is 
surprising and marvelous about these events is that the Rev RNA binding domain shows amazing 
adaptability. It thus uses different surfaces of its arginine rich helical motif (ARM) to interact with the 
RNA, as the higher order complex gets assembled. The RRE also appears to be an active player in this 
assembly, as a single point mutation in stem loop IA, a site quite distant in the linear RRE sequence 
from the primary stem loop II B, was demonstrated to reduce the affinity of the complex five-fold. 
The highly basic domain of Rev, and Rev‟s tendency to oligomerize even in the absence of RNA, 
are at least partially to blame for the fact that it has taken so long to get a crystal structure. Preparations 
of Rev protein have usually demonstrated low solubility, with the uncontrolled formation of oligomers 
as  well  as  insoluble  aggregates  whose  formation  are  probably  driven  by  its  highly  basic  domain  
[56–58]. It is well known that previous Rev crystallization attempts have been the “graveyard” projects 
in many laboratories for many years. The keys to the recent structural advances are the clever ways in 
which the researchers involved have overcome these issues. 
Previous genetic and biochemical studies had indicated that Rev oligomerization occurred through 
two  different  sets  of  hydrophobic  sequences  on  different  surfaces  of  the  protein  [59,60].  One  set 
included Leu18 and Ile55, which were needed to form a cooperative RNA-Rev dimer, and the other 
involved  Leu12  and  Leu60,  which  were  needed  for  higher  order  oligomerization.  To  weaken  the 
higher order interaction, and prevent the problem of uncontrolled oligomerization in vitro, the Frankel 
group mutated Leu12 and Leu60 to Ser and Lys and removed 46 residues from the carboxyterminus of 
Rev [3]. Another trick to increase Rev solubility at high concentrations was to initially purify Rev as a 
fusion protein with the well-folded negatively charged B1 domain of streptococcal protein G (GB1) 
[2,61]. The GB1 domain was later cleaved off with a specific protease. The authors found that the GB1 
fusion increased Rev solubility 100–1000 fold and they furthermore showed that potassium phosphate 
or sodium sulfate at 100 mM could maintain Rev in a soluble state upon removal of the fused GB1 
domain. They argue that the acidic GB1 fusion or the oxyanionic counterions helped to solubilize Rev 
by charge neutralization, acting as RNA surrogates. 
By following this protocol, Daugherty et al. obtained crystals that could be analyzed to a final 
resolution of 2.5Å [3]. Visible within the crystal lattice were the dimer interface of each asymmetric 
dimer unit, as well as the higher order oligomerization interface. Even though the oligomerization 
interface was mutated to allow crystallization, the Rev dimers in the crystal still packed against each 
other using the mutated interface. Just before this study appeared, another study by DiMattia et al. used 
Rev that was prepared in a complex with a specially engineered monoclonal Fab fragment [4]. This 
also overcame solubility issues and allowed crystallization, but the Fab fragment obscured the dimer 
interface and only the higher order oligomerization surface of Rev could be determined. The two Viruses 2011, 3                         
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higher order interface structures from both the Daugherty and DiMatta studies are nearly identical. As 
predicted, hydrophobic residues at position 12, 16 and 60 mediate the interaction. 
So what does the structure of the first 70 amino acids of Rev look like, how does the dimer form 
and  how  does  the  higher  order  complex  assemble?  The  Rev  monomer  folds  as  an  antiparallel  
helix-loop-helix structure with the two helices in a nearly parallel orientation. It is stabilized by a series 
of  hydrophobic  interactions  and  electrostatic  interactions  between  the  two  helices  and  adjacent 
residues. These interactions create a hydrophobic core that allows the monomer to dimerize by binding 
to the analogous core of a second monomer. Some of the residues involved in stabilizing the monomer, 
particularly Leu22 and Ile59 also stabilize the dimer. A diagram of this structure is shown in Figure 1, 
taken directly from Daugherty et al. [3]. 
Figure 1. Structure of the Rev Dimer. (a) Two views of a surface representation of dimer 
are shown. (b) The folded core of a Rev monomer with its functional domains highlighted 
is shown. The amino acids prominent in mediating the core structure are specified. The 
different colors of the ribbon indicate amino acid conservation among 1201 HIV-1 isolates 
in  the  Los  Alamos  Sequence  Database,  with  green  representing  the  least  conservation 
(26%) and red the highest (100%). Reprinted with permission from Macmillan Publishers 
Ltd: Nature Structural & Molecular Biology 17, 1337–1342 (2010) [3].  
 
 
The interaction between the hydrophobic core of each monomer positions them in a „V‟ shape 
arrangement with a crossing angle of 120° (see Figure 1a). This arrangement predicts how the second 
monomer would contact the RNA outside of the primary binding site (see Figure 2). Interestingly, 
contact of the second monomer with RNA would use a different face of the helical ARM, rather than 
the one used to interact with the primary binding site. This model is consistent with the binding data 
already discussed above. Binding is cooperative and involves a protein-protein interaction as well as a 
protein-RNA  interaction.  At  least  two  additional  “V”  shaped  dimers  of  Rev  also  get  recruited  to  
the  intact  RRE  in  a  cooperative  fashion  using  the  higher  order  interface  interactions  and  further 
RNA binding. 
   Viruses 2011, 3                         
 
 
488 
Figure 2. Model of the Rev dimer interacting with a model Rev Response Element (RRE) 
stem IIB binding site.  In this model, the second monomer binds cooperatively using a 
different surface of the arginine rich helical motif (ARM) to contact the RNA (red). The 
yellow residue in the diagram represents Asn40 which contacts the RNA on the “inner 
face” of ARM1 but not ARM2 which uses the “outer face” of the ARM to bind. Reprinted 
with permission from Macmillan Publishers Ltd: Nature Structural & Molecular Biology 
17, 1337–1342 (2010) [3]. 
 
 
Daugherty et al. point out that the inherent flexibility of this mode of RRE-Rev assembly, both in 
the way that the dimer forms and the way that the RNA is recognized, may be necessary to allow the  
Rev-RRE interaction to evolve and remain efficient as HIV sequence changes during the course of a 
natural infection [1]. 
This  work  is  a  long-awaited  landmark  achievement,  as  it  clearly  defines  important  structural 
features of the Rev-RRE complex. With the atomic structure of the Rev dimer and oligomer interfaces 
solved, and an increased understanding about how the RNA is recognized, the way is now open for 
rational  drug  design  that  could  lead  to  compounds  that  would  interfere  with  these  interactions. 
However, many questions still remain about the recognition of the NES in the resulting complex. As 
Daugherty et al. themselves point out, steric hindrance would appear to not allow more than one or two 
molecules  of  Crm-1  to  bind  the  complex.  They  suggest  that  the  function  of  oligomerization  may 
simply be to facilitate tight binding through cooperativity and that multimerization itself may not be 
used to recruit multiple Crm-1 molecules [3]. However, since the total number of Rev proteins that 
actually get recruited to an HIV mRNA remains an unanswered question, at this point it is difficult to 
say anything about the total number of Crm-1 molecules needed for export. In the end, the structural 
model thus sheds little light on how Rev-RRE binding eventually overcomes nuclear retention. The 
matter is further complicated by the fact that in the cell many other RNA binding proteins would also 
be expected to be bound to the RNA. Some of these are likely to be shuttle proteins, with their own 
NES sequences. Thus, the details of how Rev/RRE binding actually promotes export, is a still an 
unsolved mystery.  
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